Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2023 Earnings Call Transcript August 7, 2023 4:30 PM ET Company Participants Antony Mattessich - President & CEO Donald Notman - CFO Rabia Ozden - CMO Steve Meyers - SVP, Commercial Conference Call Participants Dane Leone - RJF Jon Wolleben - JMP Joe Catanzaro - Piper Sandler Colleen Kusy - Baird Kelly Shi - Jefferies Tara Bancroft - TD Cowen Chaitanya G - H.C. Wainwright Caroline Palomeque - Berenberg Capital Markets Operator Good day, and thank you for standing by ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR Delaware 20-5560161 (781) 357-4000 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Commo ...

• One of most common, severe diabetes complications; leading cause of blindness in working-age population *per planned protocol dosing Sources: Eye care of the patient with diabetes mellitus. American Optometric Association, Second Edition; Market Scope - 2022 Retinal Pharmaceuticals Market Report, Global Analysis 2021-2027; Market Scope Q2-2022 US Retina Quarterly Update; AAO DR Preferred Practice Pattern; JAMA Ophthalmol. 2021;139(9):946-955 (PANORAMA); Arcadu F, et al. NPJ Digit Med. 2019;2:92. • Diabeti ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Executive Officer Rabia Ozden - Chief Medical Officer Steve Meyers - Senior Vice President of Commercial Conference Call Participants Jon Wolleben - JMP Securities Joe Catanzaro - Piper Sandler Tara Bancroft - Cowen Colleen Kusy - Baird Yi Chen - H.C. Wainwright Caroline Palomeque - Berenberg Capital Markets Operator ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President & Chief Executive Officer Steve Meyers - Senior Vice President of Commercial Rabia Ozden - Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Jon Wolleben - JMP Securities Caroline Palomeque - Berenberg Joe Catanzaro - Piper Sandler Operator Good afternoon, ladies and gentlemen. Thank you for sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (State or ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Donald Notman – Chief Financial Officer Antony Mattessich – President and Chief Executive Officer Rabia Ozden – Chief Medical Officer Peter Kaiser – Chief Medical Adviser-Retina Conference Call Participants Joe Catanzaro – Piper Sandler Kambiz Yazdi – Jefferies Yi Chen – H.C. Wainwright Yuan Zhi – B. Riley Georgi Yordanov – Cowen Caroline Palomeque – Berenberg Operator Good day, and thank ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 24 Crosby Drive Bedford, MA 01730 (Address of principal executive offices) (Zip Code) (781) 357-4000 (Registrant's telephone number, ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Donald Notman - CFO Antony Mattessich - President, CEO & Director Rabia Ozden - Chief Medical Officer Conference Call Participants Jonathan Wolleben - JMP Securities Stacy Ku - Cowen and Company Yi Chen - H.C. Wainwright & Co. Joseph Catanzaro - Piper Sandler & Co. Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Ocular Therapeutix Second Quarter ...